Related Experiment Video
Updated: Jul 13, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Design and evaluation of a potential mutagen for Hepatitis C virus
Yung-Hyo Koh1, Jae Hoon Shim, Jean-Luc Girardet
1Valeant Pharmaceutical Research & Development, 3300 Hyland Ave., Costa Mesa, CA 92626, USA. ykoh@andreabiosciences.com
Abstract:
Pyrrolopyrimidine nucleoside 1 was designed and synthesized as a potential mutagen for HCV. An in vitro HCV NS5B enzymatic assay indicated that pyrrolopyrimidine triphosphate acts as a CTP analog rather than a UTP analog. The SATE-prodrug of pyrrolopyrimidine monophosphate showed a weak inhibitory activity in an HCV replicon system (EC(50)=60 microM) and did not exhibit cytotoxicity (CC(50)>100 microM). Investigation of phosphorylation events using nucleoside kinases and LC-MS analysis revealed that the second phosphorylation step, from monophosphate ester to diphosphate ester, is unfavorable.
Related Concept Videos
Mutagenicity and Carcinogenicity
Hepatitis
In vitro Mutagenesis
In-vitro Mutagenesis

